Cranbury Pharmaceuticals Receives U.S. FDA Approval for First Generic Version of Emflaza® Oral Suspension (deflazacort) for Duchenne Muscular Dystrophy

generic version of Emflaza for Duchenne

The FDA approved the first generic version of Emflaza® for treating Duchenne in the US. Cranbury Pharmaceuticals, part of Tris Pharma, has just announced that the U.S. Food and Drug Administration (FDA) approved a new generic version of Emflaza® (deflazacort) oral suspension. This medicine is used to treat Duchenne muscular dystrophy in patients who are five years old and older. The generic version of Emflaza for Duchenne is now available in the U.S. Read the full news release HERE.

What Does This Mean for those with Duchenne?

If you or your child is currently taking Emflaza, talk to your neuromuscular provider and your insurance company about if the generic version of Emflaza for Duchenne may be available to you.

How to Get the New Medicine

If you need help getting Cranbury’s generic version of Emflaza for Duchenne oral suspension, you can visit Cranbury Connects, the company’s patient assistance program. They can help you find the information you need HERE.

Choosing the Right Steroid

CureDuchenne’s A Steroid Discussion, One Disease, Many Path session can help you make informed decisions about steroids. This FUTURES session features a discussion with experts Diana Castro, MD and Nat Nasomyont, MD, MS. Watch HERE

Choosing a Steroid Drug, Dose, and Regimen: Sign up to have a one-on-one with our experts HERE

Related Posts

Share This Page

Make an Impact

You can advance the care, treatment and cure for Duchenne muscular dystrophy. Contributions in any amount can truly make a difference and can be credited to a fundraiser or event from the list below.